Anne Wojcicki, 23andMe CEO (Jordan Vonderhaar/Bloomberg via Getty Images)
August 2, 2024 10:34 AM EDT
Deals
Diagnostics

23andMe board re­jects Anne Wo­j­ci­c­ki’s take-pri­vate plan, re­quests changes

Andrew Dunn

Senior Biopharma Correspondent

CEO Anne Wo­j­ci­c­ki’s of­fer to take her ge­net­ic test­ing com­pa­ny 23andMe pri­vate for 40 cents a share has been met with re­sis­tance from her own …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

A service from the Financial Times